Amicus Therapeutics (FOLD) EBIAT (2016 - 2025)
Amicus Therapeutics (FOLD) has disclosed EBIAT for 16 consecutive years, with $1.7 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 88.53% year-over-year to $1.7 million, compared with a TTM value of -$27.1 million through Dec 2025, up 51.68%, and an annual FY2025 reading of -$27.1 million, up 51.68% over the prior year.
- EBIAT was $1.7 million for Q4 2025 at Amicus Therapeutics, down from $17.3 million in the prior quarter.
- Across five years, EBIAT topped out at $17.3 million in Q3 2025 and bottomed at -$85.3 million in Q1 2022.
- Average EBIAT over 5 years is -$36.1 million, with a median of -$38.5 million recorded in 2023.
- Peak annual rise in EBIAT hit 357.19% in 2025, while the deepest fall reached 88.53% in 2025.
- Year by year, EBIAT stood at -$83.3 million in 2021, then skyrocketed by 32.92% to -$55.9 million in 2022, then soared by 39.42% to -$33.8 million in 2023, then soared by 143.55% to $14.7 million in 2024, then crashed by 88.53% to $1.7 million in 2025.
- Business Quant data shows EBIAT for FOLD at $1.7 million in Q4 2025, $17.3 million in Q3 2025, and -$24.4 million in Q2 2025.